No Data
Pacific Shuanglin Bio-pharmacy Co., LTD's (SZSE:000403) Stock Price Dropped 6.1% Last Week; Private Companies Would Not Be Happy
Pacific Shuanglin Bio-pharmacy (000403.SZ) 40.3337 million restricted shares will be available for trading on February 26.
Pacific Shuanglin Bio-pharmacy (000403.SZ) announced that the number of restricted shares to be lifted this time is 4,033.37...
Research Reports Insights | CICC: Initiates coverage on Pacific Shuanglin Bio-pharmacy with an 'Outperform Industry' rating and a Target Price of 25.5 yuan.
The research report from China International Capital Corporation indicates that Pacific Shuanglin Bio-pharmacy (000403.SZ) is expected to exceed a thousand tons in plasma collection in 2023, joining the top tier of domestic blood product companies. After Shaanxi Coal took control, internal management is expected to continue improving, which should benefit plasma collection volumes, revenue per ton, and profits. The company anticipates that the Guangdong Shuanglin Phase II project is expected to commence production in the second half of 2025, increasing annual capacity to 1,500 tons. Additionally, the company plans to continue advancing the Pacific Shuanglin capacity enhancement project. The company expects that with the ongoing investment in new plasma collection stations, future plasma collection volumes are likely to continue increasing, and the company announced in October 2024 that plasma collection volume is expected to exceed 1 ton in 2024.
Pacific Shuanglin Bio-pharmacy (SZSE:000403) Seems To Use Debt Rather Sparingly
Investors Don't See Light At End Of Pacific Shuanglin Bio-pharmacy Co., LTD's (SZSE:000403) Tunnel
Pacific Shuanglin Bio-pharmacy (000403.SZ): Some directors, supervisors, and core management personnel intend to increase their shareholding in the company by no less than 5 million yuan.
On December 27, Gelonghui reported that Pacific Shuanglin Bio-pharmacy (000403.SZ) announced that the company recently received a notice from some of its directors, supervisors, and core management personnel regarding their voluntary Shareholding plan. Based on confidence in the company's future development prospects and a high recognition of the company's value, to promote the healthy, stable, and long-term development of the company, safeguard the interests of shareholders, and enhance investor confidence, it is planned to increase the company's shares using self-owned funds through the Exchange trading system within six months from the date of this announcement (excluding periods where laws, regulations, and the business rules of the Shenzhen Stock Exchange do not permit shareholding increases). The total amount to be increased is.
There's Reason For Concern Over Pacific Shuanglin Bio-pharmacy Co., LTD's (SZSE:000403) Price